Earnings Releases·Nov 4, 2026, 8:28 AM ET

Ocugen — Third Quarter 2026 Earnings Summary

Total revenue increased to $1.951 million for the three months ended September 30, 2026, from $1.752 million in the prior year period, while net loss narrowed to $3.598 million (vs. $20.051 million); cash and short-term investments totaled $84.6 million, supporting a runway into 2028.
OCU400 Phase 3 top-line data is expected in Q1 2027 with a subsequent BLA submission, while OCU410ST pivotal trial data is anticipated in Q2 2027; OCU410 Phase 3 ArMaDa3 dosing has commenced.
Executed an exclusive OCU400 license agreement for the Middle East and North Africa with Roots Pharmaceutical, securing up to $4 million in upfront/development milestones, $255 million in sales milestones, and a 22% royalty.
Total liabilities rose to $125.742 million as of September 30, 2026, driven by $83.117 million in new convertible notes and a $17.146 million derivative liability, resulting in a stockholders' deficit of $(17.681) million.
The company aims to achieve full LARTA approval in The Bahamas and initiate OCU400 patient enrollment by year-end 2026, while maintaining a disciplined approach toward regulatory submissions.